ArticleBMC medicine2023
Association between epicardial adipose tissue and incident heart failure mediating by alteration of natriuretic peptide and myocardial strain.
Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005121 (Framingham Heart Study), which is not on this map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Framingham Heart Study
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Identification of key proteins and pathways in myocardial infarction using machine learning approaches.Scientific reports · 2025Pooled it
- Linking abnormal fat distribution with HFpEF and diastolic dysfunction: a systematic review, meta-analysis, and meta-regression of observational studies.Lipids in health and disease · 2024Pooled it
- Weight-adjusted waist index and risk of cardiovascular and all-cause mortality in chronic kidney disease: NHANES 2005-2018 analysis of 5,381 adults.Renal failure · 2026Article
- Review
- Epicardial Adipose Tissue in Diabetic Heart Disease: Impact on Cardiac Function and Modulation Strategies, a Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- The Serpin Superfamily in Adipose Tissue Remodeling: Molecular Drivers of Immune-Metabolic Crosstalk and Insulin Sensitivity.Biology · 2026Review
- Depot-Specific Cardiorenal Adipose Remodeling with SGLT2i in Chronic Kidney Disease.Journal of clinical medicine · 2026Article
- Cardiac Magnetic Resonance to Define Myocardial Structure in Obesity-Associated Heart Failure.Current cardiology reports · 2026Review
- Review
- The Role of GDF-15 in Heart Failure and Biomarker Potential-From Basic Science to Clinical Praxis.Biology · 2026Review
- Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?European heart journal · 2026Review
- Epicardial adipose tissue as a metabolically active visceral fat depot: an emerging target in cardiovascular disease.Frontiers in cardiovascular medicine · 2026Review
- Heart-guarding or heart-harming? The dual role of epicardial adipose tissue in cardiovascular health and disease.International journal of obesity (2005) · 2025Review
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
- Pericardial adipose tissue promotes transition to heart failure with reduced ejection fraction upon pressure-overload in mice.Basic research in cardiology · 2025Article
- Epicardial adipose tissue volume is associated with impaired left ventricular strain in patients with metabolic syndrome: the mediating role of myocardial energetic efficiency.Cardiovascular diabetology · 2025Article
- Role of epicardial adipose tissue in heart failure with preserved ejection fraction: An emerging molecular mechanism and therapeutic potential.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Review
- Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF.Cardiovascular diabetology · 2025Review
- Cardiac magnetic resonance quantified epicardial fat volume is associated with complex coronary artery disease among diabetics.Cardiovascular diabetology · 2025Article
- The association between obesity indicators and mortality among individuals with hyperlipidemia: evidence from the NHANES 2003-2018.Lipids in health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpicardial adipose tissue (EAT) has been suggested to exert deleterious effects on myocardium and cardiovascular disease (CVD) consequence. We evaluated the associations of EAT thickness with adverse outcomes and its potential mediators in the community.
methodsParticipants without heart failure (HF) who had undergone cardiac magnetic resonance (CMR) to measure EAT thickness over the right ventricular free wall from the Framingham Heart Study were included. The correlation of EAT thickness with 85 circulating biomarkers and cardiometric parameters was assessed in linear regression models. The occurrence of HF, atrial fibrillation, coronary heart disease (CHD), and other adverse events was tracked since CMR was implemented. Their associations with EAT thickness and the mediators were evaluated using Cox regression and causal mediation analysis.
resultsOf 1554 participants, 53.0% were females. Mean age, body mass index, and EAT thickness were 63.3 years, 28.1 kg/m
conclusionsEAT thickness was correlated with inflammation and fibrosis-related circulating biomarkers, cardiac concentric change, myocardial strain impairment, incident HF risk, and overall CVD risk. NT-proBNP and GLS might partially mediate the effect of thickened EAT on the risk of HF. EAT could refine the assessment of CVD risk and become a new therapeutic target of cardiometabolic diseases.
trial registrationURL: https://clinicaltrials.gov . Identifier: NCT00005121.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.